State Street
SMMT icon

State Street’s Summit Therapeutics SMMT Stock Holding History

State Street’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133M Buy
7,028,160
+391,799
+6% +$6.34M ﹤0.01% 1201
2025
Q4 		$116M Buy
6,636,361
+274,425
+4% +$5.16M ﹤0.01% 1269
2025
Q3 		$131M Buy
6,361,936
+2,344,239
+58% +$56.8M ﹤0.01% 1184
2025
Q2 		$85.5M Sell
4,017,697
-833,691
-17% -$19M ﹤0.01% 1393
2025
Q1 		$93.6M Sell
4,851,388
-751,522
-13% -$15.1M ﹤0.01% 1300
2024
Q4 		$100M Buy
5,602,910
+2,134,396
+62% +$41.4M ﹤0.01% 1329
2024
Q3 		$76M Sell
3,468,514
-654,623
-16% -$9.15M ﹤0.01% 1485
2024
Q2 		$32.2M Sell
4,123,137
-3,991,093
-49% -$21.6M ﹤0.01% 1894
2024
Q1 		$33.6M Buy
8,114,230
+5,658,062
+230% +$22.5M ﹤0.01% 1930
2023
Q4 		$6.41M Buy
2,456,168
+189,599
+8% +$390K ﹤0.01% 2828
2023
Q3 		$4.24M Buy
2,266,569
+12,594
+0.6% +$24K ﹤0.01% 2997
2023
Q2 		$5.66M Buy
2,253,975
+2,131,675
+1,743% +$3.89M ﹤0.01% 2935
2023
Q1 		$214K Buy
122,300
+34,400
+39% +$93.8K ﹤0.01% 4057
2022
Q4 		$374K Buy
+87,900
New +$160K ﹤0.01% 3865
2022
Q2 		– Sell
-313,401
Closed -$768K – 4970
2022
Q1 		$768K Sell
313,401
-23,713
-7% -$59.8K ﹤0.01% 3891
2021
Q4 		$907K Buy
337,114
+916
+0.3% +$4.4K ﹤0.01% 3838
2021
Q3 		$1.68M Buy
336,198
+79,498
+31% +$570K ﹤0.01% 3655
2021
Q2 		$1.92M Buy
+256,700
New +$1.68M ﹤0.01% 3556

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street's SMMT Position: Q1 2026 in Review

State Street increased its Summit Therapeutics (SMMT) stake by 5.9% in Q1 2026, buying an estimated $6.34M and bringing the position to 7,028,160 shares worth $133M. The position accounts for ﹤0.01% of the portfolio, ranked #1201.

State Street first reported a position in SMMT in Q2 2021 and has held it in 18 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • State Street held 7,028,160 shares of Summit Therapeutics worth $133M as of Q1 2026.
  • State Street bought 391,799 Summit Therapeutics shares in Q1 2026, an estimated $6.34M.
  • Summit Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #1201 holding.
  • State Street first reported a position in Summit Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.